Sichenzia Ross Friedman Ference LLP Advises Laidlaw & Company on $10 million Secondary Public Offering of Cyclacel Pharmaceuticals, Inc.
NEW YORK, April 8, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Laidlaw & Company (UK) Ltd. as sole underwriter in a $10 million secondary public offering for Cyclacel Pharmaceuticals, Inc. (“CYCC.” NASDAQ). The underwriting was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of 2,857,143 shares of common stock at an offering price of $3.50 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Richard Friedman and Stephen Cohen.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP代表Aegis Capital Corp.以230万美元公开发行Sigma Labs，Inc。的普通股 - August 3, 2019
- Sichenzia Ross Ference LLP在2019年第二季度被评为最佳发行人律师 - July 24, 2019
- Sichenzia Ross Ference LLP代表ThinkEquity以135万美元的方式公开发行Immuron Limited的ADS - July 23, 2019